To confirm that these anti-tumor effects were based on the specific knockdown of the target genes, HER2 levels were analyzed by immunohistochemistry and revealed reduced HER2 protein levels upon PEI/siHER2 treatment to the negative control PEI/siUR group (Figure 2B). This evidence concerns the gene ERBB2 and neoplasm.